The effect of metformin in clinical studies on knee osteoarthritis: an updated systematic review and meta-analysis
Abstract
Objectives: Metformin is regarded as a potential drug for the treatment of knee osteoarthritis (KOA), but its efficacy remains unclear. This systematic review and meta-analysis aims to evaluate the efficacy of metformin in the treatment of KOA.
Methods: According to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we searched three literature databases, including PubMed, Web of Science and EMBASE, and conducted a systematic review and meta-analysis of randomized controlled trials and cohort studies up to April 1, 2025, studies evaluating the use of metformin in the treatment of KOA were included. Hazard ratio (RR), standard mean difference (SMD), and the corresponding 95% confidence interval (CI) were used as aggregated statistics. This systematic review is registered on RROSPERO (CRD420251026750).
Results: A total of six eligible studies included 4,628 patients (1,489 patients use metformin versus 3,139 patients non-use). The main observation outcome was the score of the pain scale (WOMAC, KOOS, VAS, etc.) of the knee joint and the incidence of total knee arthroplasty (TKA) is a secondary outcome. Analysis of the included population the included population reveals that the BMI levels of all individuals were at the overweight range. In this situation, the comprehensive results show that regardless of different conventional treatment methods, courses of treatment and doses, combined metformin treatment in the incidence of joint…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 4,628 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.